14 June 2023
Aptamer Group plc
("Aptamer" or "the Group")
Response to Share Price Movement
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, notes the significant increase in the share price today. Other than the non-regulatory announcement earlier today regarding the Group's partnership with NeuroBio to develop Optimers for a potential Alzheimer's disease diagnostic, the Group is not aware of any material commercial or operational reason for the significant increase in its share price.
As notified in the Trading Update on 5 May 2023, Aptamer continues to explore a range of funding options including non-dilutive and dilutive sources to strengthen the balance sheet. Cash at the end of May 2023 stood at £0.7m.
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Rob Quinn +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Cara Murphy +44 (0) 20 3100 2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.